Table 1.

Differential effect of several treatments on the agonist-induced aggregation, adhesion, and fibrinogen binding to CHO cells coexpressing the human PAF and fibrinogen receptors

AggregationAdhesionFg binding (%)
PAF ant (200 nM) − − ND  
PTX (200 ng/mL) − ND  
RGDS (1 mM) − − 0  
H7 (25 μM) − 75  
Staurosporine (0.5 μM) − 73 
BIM-I (1 μM) − 91  
EDTA (5 mM) − − 
W7 (20 μM) − 22  
BAPTA-AM (100 μM) − 0  
Genistein (100 μM) 100 
PD98059 (50 μM) ND  
Ly294002 (20 μM) ND  
db-cAMP (500 μM) ND 
AggregationAdhesionFg binding (%)
PAF ant (200 nM) − − ND  
PTX (200 ng/mL) − ND  
RGDS (1 mM) − − 0  
H7 (25 μM) − 75  
Staurosporine (0.5 μM) − 73 
BIM-I (1 μM) − 91  
EDTA (5 mM) − − 
W7 (20 μM) − 22  
BAPTA-AM (100 μM) − 0  
Genistein (100 μM) 100 
PD98059 (50 μM) ND  
Ly294002 (20 μM) ND  
db-cAMP (500 μM) ND 

The effect of the different agents on the PAF-induced aggregation and adhesion of CHO-αIIbβ3-PAFR cells was assessed as described in “Materials and methods.” Positive (+) or negative (−) signs indicate the presence or absence of adhesion or aggregation. Fibrinogen binding is expressed as percent of the Fg bound to PAF-stimulated cells in the absence of antagonists.

CHO indicates Chinese hamster ovary; PAF, platelet-activating factor; PAF ant, PAF antagonist; PTX, pertussis toxin; RGDS, Arg-Gly-Asp-Ser; EDTA, ethylenediaminetetraacetic acid; ND, not determined.

or Create an Account

Close Modal
Close Modal